Journal
ROYAL SOCIETY OPEN SCIENCE
Volume 5, Issue 11, Pages -Publisher
ROYAL SOC
DOI: 10.1098/rsos.181321
Keywords
cancer therapy; Connectivity Map; drug repurposing; histone deacetylase; polypharmacology; topoisomerase
Categories
Funding
- Health and welfare surcharge of tobacco products of Taiwan [MOHW107-TDU-B-212-114020]
- Ministry of Science and Technology of Taiwan [MOST105-2314-B-195-009-MY3]
- Mackay Memorial Hospital of Taiwan [MMH-107-13, MMH-107-86]
- Taipei Medical University of Taiwan [TMU106-F-005]
- Taipei Medical University - Shuang Ho Hospital of Taiwan [104TMU-SHH-03]
Ask authors/readers for more resources
Drug repurposing aims to find novel indications of clinically used or experimental drugs. Because drug data already exist, drug repurposing may save time and cost, and bypass safety concerns. Polypharmacology, one drug with multiple targets, serves as a basis for drug repurposing. Large-scale databases have been accumulated in recent years, and utilization and integration of these databases would be highly helpful for polypharmacology and drug repurposing. The Connectivity Map (CMap) is a database collecting gene-expression profiles of drug-treated human cancer cells, which has been widely used for investigation of polypharmacology and drug repurposing. In this study, we integrated the next-generation L1000-based CMap and an analytic Web tool, the L1000FWD, for systematic analyses of polypharmacology and drug repurposing. Two different types of anti-cancer drugs were used as proof-of-concept examples, including histone deacetylase (HDAC) inhibitors and topoisomerase inhibitors. We identified KM-00927 and BRD-K75081836 as novel HDAC inhibitors and mitomycin C as a topoisomerase IIB inhibitor. Our study provides a prime example of utilization and integration of the freely available public resources for systematic polypharmacology analysis and drug repurposing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available